Epizyme (EPZM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Prothena beats on earnings and revenues in the first quarter of 2022. The company's progress with its AD pipeline is encouraging.
Prothena (PRTA) delivered earnings and revenue surprises of 8.24% and 401.30%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?